open access

Vol 91, No 9 (2020)
Research paper
Published online: 2020-09-14
Get Citation

Subcutaneous rifampicin versus povidone-iodine for the prevention of incisional surgical site infections following gynecologic oncology surgery — a prospective, randomized, controlled trial

Özge Kömürcü Karuserci1, Özcan Balat1
·
Pubmed: 33030730
·
Ginekol Pol 2020;91(9):513-518.
Affiliations
  1. Gaziantep University, Turkey

open access

Vol 91, No 9 (2020)
ORIGINAL PAPERS Gynecology
Published online: 2020-09-14

Abstract

Objectives: Surgical site infection (SSI) following gynecologic oncology surgery is a severe problem for both patient
and surgeon in terms of increasing morbidity, length of hospital stay, anxiety, and costs. In this prospective, randomized,
controlled study we investigated the effect of subcutaneous rifampicin and povidone-iodine on incisional SSI following
gynecologic oncology surgery.
Material and methods: Three hundred patients scheduled for abdominal surgery due to any malign gynecological pathology
were randomly assigned into one of three groups of 100 members each, as follows: the subcutaneous tissue was
irrigated with saline in Group 1; saline + 10% povidone iodine in Group 2; saline + rifampicin in Group 3. Patients were
invited to follow-up once every 10 days in a 30-day period for evaluation. Patients who developed a superficial incisional
SSI were recorded.
Results: No significant relationship was observed between the SSI and the subcutaneous agents used (p = 0.332). It was
observed that there was a statistically significant increase in the rate of incisional surgical site infections as the period
of hospitalization (p = 0.044), patient’s age (p = 0.003), existence of comorbidities (p = 0.001), and perioperative blood
transfusion (p = 0.021) increased.
Conclusions: Subcutaneous agents are not effective in preventing surgical site infections after gynecologic oncology
surgeries. Further large-scale prospective randomized controlled studies may provide other options to prevent SSIs.

Abstract

Objectives: Surgical site infection (SSI) following gynecologic oncology surgery is a severe problem for both patient
and surgeon in terms of increasing morbidity, length of hospital stay, anxiety, and costs. In this prospective, randomized,
controlled study we investigated the effect of subcutaneous rifampicin and povidone-iodine on incisional SSI following
gynecologic oncology surgery.
Material and methods: Three hundred patients scheduled for abdominal surgery due to any malign gynecological pathology
were randomly assigned into one of three groups of 100 members each, as follows: the subcutaneous tissue was
irrigated with saline in Group 1; saline + 10% povidone iodine in Group 2; saline + rifampicin in Group 3. Patients were
invited to follow-up once every 10 days in a 30-day period for evaluation. Patients who developed a superficial incisional
SSI were recorded.
Results: No significant relationship was observed between the SSI and the subcutaneous agents used (p = 0.332). It was
observed that there was a statistically significant increase in the rate of incisional surgical site infections as the period
of hospitalization (p = 0.044), patient’s age (p = 0.003), existence of comorbidities (p = 0.001), and perioperative blood
transfusion (p = 0.021) increased.
Conclusions: Subcutaneous agents are not effective in preventing surgical site infections after gynecologic oncology
surgeries. Further large-scale prospective randomized controlled studies may provide other options to prevent SSIs.

Get Citation

Keywords

gynecologic surgical oncology; povidone-iodine; rifampicin; surgical site infection

About this article
Title

Subcutaneous rifampicin versus povidone-iodine for the prevention of incisional surgical site infections following gynecologic oncology surgery — a prospective, randomized, controlled trial

Journal

Ginekologia Polska

Issue

Vol 91, No 9 (2020)

Article type

Research paper

Pages

513-518

Published online

2020-09-14

Page views

904

Article views/downloads

998

DOI

10.5603/GP.a2020.0134

Pubmed

33030730

Bibliographic record

Ginekol Pol 2020;91(9):513-518.

Keywords

gynecologic surgical oncology
povidone-iodine
rifampicin
surgical site infection

Authors

Özge Kömürcü Karuserci
Özcan Balat

References (35)
  1. Mahdi H, Gojayev A, Buechel M, et al. Surgical site infection in women undergoing surgery for gynecologic cancer. Int J Gynecol Cancer. 2014; 24(4): 779–786.
  2. Quiroga-Garza A, Valdivia-Balderas JM, Trejo-Sánchez MÁ, et al. A Prospective, Randomized, Controlled Clinical Trial to Assess Use of 2% Lidocaine Irrigation to Prevent Abdominal Surgical Site Infection. Ostomy Wound Manage. 2017; 63(8): 12–21.
  3. Bakkum-Gamez JN, Dowdy SC, Borah BJ, et al. Predictors and costs of surgical site infections in patients with endometrial cancer. Gynecol Oncol. 2013; 130(1): 100–106.
  4. Lake AG, McPencow AM, Dick-Biascoechea MA, et al. Surgical site infection after hysterectomy. Am J Obstet Gynecol. 2013; 209(5): 490.e1–490.e9.
  5. Leaper D, Ousey K. Evidence update on prevention of surgical site infection. Curr Opin Infect Dis. 2015; 28(2): 158–163.
  6. Berríos-Torres SI, Umscheid CA, Bratzler DW, et al. Healthcare Infection Control Practices Advisory Committee. Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017. JAMA Surg. 2017; 152(8): 784–791.
  7. Lachiewicz MP, Moulton LJ, Jaiyeoba O. Pelvic surgical site infections in gynecologic surgery. Infect Dis Obstet Gynecol. 2015; 2015: 614950.
  8. Badia JM, Casey AL, Petrosillo N, et al. Impact of surgical site infection on healthcare costs and patient outcomes: a systematic review in six European countries. J Hosp Infect. 2017; 96(1): 1–15.
  9. Webster J, Osborne S, Webster J, et al. Preoperative bathing or showering with skin antiseptics to prevent surgical site infection. Cochrane Database Syst Rev. 2006; 93(2): CD004985–1341.
  10. Allegranzi B, Zayed B, Bischoff P, et al. WHO Guidelines Development Group, WHO Guidelines Development Group. New WHO recommendations on preoperative measures for surgical site infection prevention: an evidence-based global perspective. Lancet Infect Dis. 2016; 16(12): e276–e287.
  11. Demir N, Peker E, Gülşen İ, et al. Powder Topical Rifampin for Reducing Infections After Neural Tube Defect Surgery in Infants. World Neurosurg. 2016; 95: 165–170.
  12. Weber JM, Sheridan RL, Fagan S, et al. Incidence of catheter-associated bloodstream infection after introduction of minocycline and rifampin antimicrobial-coated catheters in a pediatric burn population. J Burn Care Res. 2012; 33(4): 539–543.
  13. Shiels SM, Tennent DJ, Wenke JC. Topical rifampin powder for orthopedic trauma part I: Rifampin powder reduces recalcitrant infection in a delayed treatment musculoskeletal trauma model. J Orthop Res. 2018; 36(12): 3136–3141.
  14. Komurcu Ka, Sucu S, Özcan Ç, et al. Topical Rifampicin versus Povidone-Iodine for the Prevention of Incisional Surgical Site Infections Following Benign Gynecologic Surgery: A Prospective, Randomized, Controlled Trial. New Microbiol. 2019; 42(4): 205–209.
  15. Lippitt MH, Fairbairn MG, Matsuno R, et al. Outcomes Associated With a Five-Point Surgical Site Infection Prevention Bundle in Women Undergoing Surgery for Ovarian Cancer. Obstet Gynecol. 2017; 130(4): 756–764.
  16. Horan TC, Gaynes RP, Martone WJ, et al. CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Am J Infect Control. 1992; 20(5): 271–274.
  17. Solomkin JS, Mazuski J, Blanchard JC, et al. Introduction to the Centers for Disease Control and Prevention and the Healthcare Infection Control Practices Advisory Committee Guideline for the Prevention of Surgical Site Infections. Surg Infect (Larchmt). 2017; 18(4): 385–393.
  18. De Nardo P, Gentilotti E, Nguhuni B, et al. Post-caesarean section surgical site infections at a Tanzanian tertiary hospital: a prospective observational study. J Hosp Infect. 2016; 93(4): 355–359.
  19. Tuuli M, Liu J, Stout M, et al. 4: Chlorhexidine-alcohol compared with iodine-alcohol for preventing surgical-site infection at cesarean: a randomized controlled trial. American Journal of Obstetrics and Gynecology. 2016; 214(1): S3–S4.
  20. Steiner HL, Strand EA. Surgical-site infection in gynecologic surgery: pathophysiology and prevention. Am J Obstet Gynecol. 2017; 217(2): 121–128.
  21. Uppal S, Bazzi A, Reynolds RK, et al. Chlorhexidine-Alcohol Compared With Povidone-Iodine for Preoperative Topical Antisepsis for Abdominal Hysterectomy. Obstet Gynecol. 2017; 130(2): 319–327.
  22. Rubin RH. Surgical wound infection: epidemiology, pathogenesis, diagnosis and management. BMC Infect Dis. 2006; 6: 171.
  23. Nugent EK, Hoff JT, Gao F, et al. Wound complications after gynecologic cancer surgery. Gynecol Oncol. 2011; 121(2): 347–352.
  24. Heal CF, Banks JL, Lepper P, et al. Meta-analysis of randomized and quasi-randomized clinical trials of topical antibiotics after primary closure for the prevention of surgical-site infection. Br J Surg. 2017; 104(9): 1123–1130.
  25. Karaarslan N, Yilmaz I, Ozbek H, et al. Is Implant Washing and Wound Irrigation with Rifampicin Effective for Preventing Surgical Site Infections in Lumbar Instrumentation? Turk Neurosurg. 2018; 28(6): 904–909.
  26. McHugh SM, Collins CJ, Corrigan MA, et al. The role of topical antibiotics used as prophylaxis in surgical site infection prevention. J Antimicrob Chemother. 2011; 66(4): 693–701.
  27. Mueller TC, Loos M, Haller B, et al. Intra-operative wound irrigation to reduce surgical site infections after abdominal surgery: a systematic review and meta-analysis. Langenbecks Arch Surg. 2015; 400(2): 167–181.
  28. Edmiston CE, Leaper DJ. Intra-Operative Surgical Irrigation of the Surgical Incision: What Does the Future Hold-Saline, Antibiotic Agents, or Antiseptic Agents? Surg Infect (Larchmt). 2016; 17(6): 656–664.
  29. Ploegmakers IBM, Olde Damink SWM, Breukink SO. Alternatives to antibiotics for prevention of surgical infection. Br J Surg. 2017; 104(2): e24–e33.
  30. Magann EF, Chauhan SP, Rodts-Palenik S, et al. Subcutaneous stitch closure versus subcutaneous drain to prevent wound disruption after cesarean delivery: a randomized clinical trial. Am J Obstet Gynecol. 2002; 186(6): 1119–1123.
  31. Panici PB, Zullo MA, Casalino B, et al. Subcutaneous drainage versus no drainage after minilaparotomy in gynecologic benign conditions: a randomized study. Am J Obstet Gynecol. 2003; 188(1): 71–75.
  32. Gurusamy KS, Toon CD, Davidson BR. Subcutaneous closure versus no subcutaneous closure after non-caesarean surgical procedures. Cochrane Database Syst Rev. 2014(1): CD010425.
  33. Awad SS. Adherence to surgical care improvement project measures and post-operative surgical site infections. Surg Infect (Larchmt). 2012; 13(4): 234–237.
  34. Bogani G, Rossetti D, Ditto A, et al. Minimally invasive surgery improves short-term outcomes of nerve-sparing radical hysterectomy in patients with cervical cancer: a propensity-matched analysis with open abdominal surgery. J Gynecol Oncol. 2019; 30(2): e27.
  35. Xiao H, Quan Hu, Pan S, et al. Impact of peri-operative blood transfusion on post-operative infections after radical gastrectomy for gastric cancer: a propensity score matching analysis focusing on the timing, amount of transfusion and role of leukocyte depletion. J Cancer Res Clin Oncol. 2018; 144(6): 1143–1154.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl